MindWalk Holdings Future Growth
Future criteria checks 1/6
MindWalk Holdings is forecast to grow earnings and revenue by 46.7% and 15.8% per annum respectively while EPS is expected to grow by 47.2% per annum.
Key information
46.7%
Earnings growth rate
47.18%
EPS growth rate
| Life Sciences earnings growth | 17.0% |
| Revenue growth rate | 15.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 15 Apr 2026 |
Recent future growth updates
Recent updates
The Asymmetric TechBio Play: MindWalk Holdings and the Valuation Disconnect
MindWalk Holdings Corp. (NASDAQ: HYFT) presents a classic case of market mispricing driven by a transitional lag.MindWalk Holdings Corp.'s (NASDAQ:HYFT) P/S Is Still On The Mark Following 38% Share Price Bounce
MindWalk Holdings Corp. ( NASDAQ:HYFT ) shareholders have had their patience rewarded with a 38% share price jump in...MindWalk Holdings: Repositioned TechBio Platform With Early LensAI Proof Points
Summary MindWalk Holdings (HYFT) has pivoted to an asset-light, AI-driven techbio platform, leveraging its HYFT and LensAI technologies for in silico drug discovery. LensAI's early successes include a dual-action GLP-1 agonist and a universal dengue vaccine candidate, highlighting HYFT's practical potential and commercial promise. HYFT reported record quarterly sales, improved margins, and a strengthened balance sheet post-divestiture. At an $75 million valuation, HYFT remains undervalued relative to other techbio players; I assign a Buy rating based on its platform, partnerships, and growth outlook. Read the full article on Seeking AlphaEven With A 72% Surge, Cautious Investors Are Not Rewarding ImmunoPrecise Antibodies Ltd.'s (NASDAQ:IPA) Performance Completely
Despite an already strong run, ImmunoPrecise Antibodies Ltd. ( NASDAQ:IPA ) shares have been powering on, with a gain...
AI Driven Partnerships Will Open New Biotech Opportunities
Strategic partnerships and tech collaborations are anticipated to boost revenue streams, improve net margins, and enhance operational efficiency.ImmunoPrecise Antibodies Ltd.'s (NASDAQ:IPA) Shares Leap 28% Yet They're Still Not Telling The Full Story
ImmunoPrecise Antibodies Ltd. ( NASDAQ:IPA ) shareholders would be excited to see that the share price has had a great...Will ImmunoPrecise Antibodies (NASDAQ:IPA) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Even With A 30% Surge, Cautious Investors Are Not Rewarding ImmunoPrecise Antibodies Ltd.'s (NASDAQ:IPA) Performance Completely
ImmunoPrecise Antibodies Ltd. ( NASDAQ:IPA ) shares have had a really impressive month, gaining 30% after a shaky...ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny
ImmunoPrecise Antibodies Ltd. ( NASDAQ:IPA ) shareholders that were waiting for something to happen have been dealt a...ImmunoPrecise Antibodies reports FQ1 results
ImmunoPrecise Antibodies press release (NASDAQ:IPA): FQ1 Revenue of C$4.7M (+2.2% Y/Y). As of July 31, 2022, the company held cash of C$19.2M as compared to C$30.0M as of April 30, 2022, and had working capital of C$21.7M. The company’s internal forecast indicates the cash on hand will sustain its existing operations for at least 12 months.Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 4/30/2029 | 33 | -3 | -6 | -5 | 2 |
| 4/30/2028 | 26 | -8 | -11 | -9 | 2 |
| 4/30/2027 | 20 | -12 | -13 | -12 | 2 |
| 4/30/2026 | 16 | -14 | -9 | -10 | 3 |
| 1/31/2026 | 28 | -12 | -12 | -11 | N/A |
| 10/31/2025 | 27 | -30 | -10 | -9 | N/A |
| 7/31/2025 | 25 | -30 | -10 | -9 | N/A |
| 4/30/2025 | 25 | -30 | -7 | -6 | N/A |
| 1/31/2025 | 14 | -47 | -8 | -7 | N/A |
| 10/31/2024 | 18 | -28 | -8 | -7 | N/A |
| 7/31/2024 | 21 | -27 | -6 | -4 | N/A |
| 4/30/2024 | 25 | -26 | -5 | -3 | N/A |
| 1/31/2024 | 24 | -14 | -5 | -4 | N/A |
| 10/31/2023 | 23 | -16 | -7 | -6 | N/A |
| 7/31/2023 | 22 | -21 | -12 | -10 | N/A |
| 4/30/2023 | 21 | -27 | -21 | -20 | N/A |
| 1/31/2023 | 20 | -26 | -21 | -19 | N/A |
| 10/31/2022 | 20 | -25 | -23 | -21 | N/A |
| 7/31/2022 | 19 | -23 | -20 | -19 | N/A |
| 4/30/2022 | 19 | -17 | -11 | -10 | N/A |
| 1/31/2022 | 19 | -17 | -10 | -9 | N/A |
| 10/31/2021 | 19 | -15 | -6 | -4 | N/A |
| 7/31/2021 | 19 | -10 | -4 | -2 | N/A |
| 4/30/2021 | 18 | -7 | -2 | -1 | N/A |
| 1/31/2021 | 17 | -3 | -1 | 1 | N/A |
| 10/31/2020 | 17 | -3 | 0 | 1 | N/A |
| 7/31/2020 | 15 | -3 | -1 | -1 | N/A |
| 4/30/2020 | 14 | -5 | -2 | -1 | N/A |
| 1/31/2020 | 13 | -8 | -3 | -3 | N/A |
| 10/31/2019 | 11 | -8 | N/A | -3 | N/A |
| 7/31/2019 | 11 | -9 | N/A | -3 | N/A |
| 4/30/2019 | 11 | -8 | N/A | -3 | N/A |
| 1/31/2019 | 10 | -6 | N/A | -3 | N/A |
| 10/31/2018 | 9 | -6 | N/A | -3 | N/A |
| 7/31/2018 | 8 | -5 | N/A | -2 | N/A |
| 4/30/2018 | 5 | -5 | N/A | -3 | N/A |
| 1/31/2018 | 4 | -4 | N/A | -3 | N/A |
| 10/31/2017 | 3 | -7 | N/A | -3 | N/A |
| 7/31/2017 | 2 | -6 | N/A | -2 | N/A |
| 4/30/2017 | 3 | -5 | N/A | -1 | N/A |
| 1/31/2017 | 3 | -4 | N/A | 0 | N/A |
| 10/31/2016 | 3 | 1 | N/A | 1 | N/A |
| 7/31/2016 | 2 | 0 | N/A | 0 | N/A |
| 4/30/2016 | 2 | 0 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HYFT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HYFT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HYFT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HYFT's revenue (15.8% per year) is forecast to grow faster than the US market (13% per year).
High Growth Revenue: HYFT's revenue (15.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if HYFT's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/14 12:19 |
| End of Day Share Price | 2026/07/14 00:00 |
| Earnings | 2026/01/31 |
| Annual Earnings | 2025/04/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MindWalk Holdings Corp. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tania Armstrong-Whitworth | ATB Cormark Historical (Cormark Securities) |
| Robert Wasserman | Benchmark Company |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |